2019 was another big year for drug discovery, with 29 FDA novel drug approvals for small molecules1 and 3 for antibody-drug-conjugates so far.2

Chris De Savi put together a great compilation of the molecules on LinkedIn recently, and here’s a “fast-follower” updated visual summary of the small molecules with their mechanism of action, indication, and dosing regimen listed.3 Happy new year, and looking forward to a great 2020! You can find a higher resolution PDF at the bottom of the page.

2019 Small Molecule Drug Approvals
Note: Istradefylline (Nourianz) not included since it was approved in Japan in 2013.

2019 Small Molecule Drug Approvals PDF Download:

Subscribe to get a download link to the PDF by e-mail.
SUBSCRIBE & DOWNLOAD

send download link to:

I confirm that I have read and agree to the Terms of Use and Privacy Policy.

Explore drughunter.com for more.

  1. Including istradefylline which was first approved in Japan, but not including brilliant blue G, fluorodopa F18, Ga-68-DOTATOC, bremelanotide, afamelanotide, and ferric maltol, which could all be considered small molecules by some definitions: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019
  2. The ADC approvals include the anti-CD79b agent polatuzumab vedotin (Polivy), the anti-nectin-4 agent enfortumab vedotin (Padcev), and the anti-HER2 agent fam-trastuzumab deruxtecan (Enhertu), all for oncology.
  3. From respective FDA drug labels.